JP2018516554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516554A5 JP2018516554A5 JP2017558425A JP2017558425A JP2018516554A5 JP 2018516554 A5 JP2018516554 A5 JP 2018516554A5 JP 2017558425 A JP2017558425 A JP 2017558425A JP 2017558425 A JP2017558425 A JP 2017558425A JP 2018516554 A5 JP2018516554 A5 JP 2018516554A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody fragment
- region
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166966.0 | 2015-05-08 | ||
| EP15166966.0A EP3091032A1 (en) | 2015-05-08 | 2015-05-08 | Humanized antibody or fragment thereof specific for cd3 |
| PCT/EP2016/060148 WO2016180721A1 (en) | 2015-05-08 | 2016-05-06 | Humanized antibody or fragment thereof specific for cd3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516554A JP2018516554A (ja) | 2018-06-28 |
| JP2018516554A5 true JP2018516554A5 (enExample) | 2019-06-06 |
| JP6987640B2 JP6987640B2 (ja) | 2022-01-05 |
Family
ID=53051759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558425A Active JP6987640B2 (ja) | 2015-05-08 | 2016-05-06 | Ｃｄ３に特異的なヒト化抗体またはその断片 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180112000A1 (enExample) |
| EP (2) | EP3091032A1 (enExample) |
| JP (1) | JP6987640B2 (enExample) |
| CN (1) | CN107889492B (enExample) |
| CA (1) | CA2985251C (enExample) |
| ES (1) | ES2954183T3 (enExample) |
| WO (1) | WO2016180721A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| EP3336545A1 (en) * | 2016-12-13 | 2018-06-20 | Miltenyi Biotec GmbH | Reversible labeling of antigens in biological specimens |
| CA3054939A1 (en) | 2017-03-03 | 2018-09-07 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
| MX2019013184A (es) * | 2017-05-08 | 2020-02-07 | Adimab Llc | Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. |
| ES2984950T3 (es) * | 2018-05-23 | 2024-10-31 | Pfizer | Anticuerpos específicos para CD3 y sus usos |
| GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
| CN113874399B (zh) * | 2019-05-23 | 2025-07-11 | 维洛斯生物股份有限公司 | 抗ror1/抗cd3双特异性结合分子 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| WO2022045247A1 (ja) * | 2020-08-27 | 2022-03-03 | 学校法人順天堂 | 抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物 |
| US20250074981A1 (en) * | 2021-04-06 | 2025-03-06 | Memorial Sloan-Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| JP2024533488A (ja) * | 2021-09-13 | 2024-09-12 | シャンドン シムセレ バイオファーマシューティカル カンパニー リミテッド | 抗ヒトｃｄ３抗体及びその応用 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| KR20260005358A (ko) | 2023-04-27 | 2026-01-09 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자 |
| CN121443743A (zh) | 2023-05-23 | 2026-01-30 | 赛纳生物技术公司 | 串联融合剂和相关脂质颗粒 |
| WO2025034203A1 (en) * | 2023-08-07 | 2025-02-13 | Memorial Sloan-Kettering Cancer Center | Improved methods for producing cells |
| WO2025078492A1 (en) | 2023-10-13 | 2025-04-17 | Miltenyi Biotec B.V. & Co. KG | Cd3-targeted nipah-pseudotyped lentiviral vector particles |
| WO2025109111A1 (en) | 2023-11-22 | 2025-05-30 | Immudex Aps | Immune cell activating multimers |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658019A (en) | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| AU6642390A (en) | 1989-10-27 | 1991-05-31 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2164226C (en) | 1993-06-04 | 2011-02-08 | Carl H. June | Methods for selectively stimulating proliferation of t cells |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| JP4066166B2 (ja) | 2000-12-26 | 2008-03-26 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 抗−ｃｄ２８抗体 |
| AU2003216436A1 (en) * | 2002-02-08 | 2003-09-02 | Life Technologies Corporation | Compositions and methods for restoring immune responsiveness in patients with immunological defects |
| AU2006298188B2 (en) * | 2005-09-30 | 2012-03-15 | Takara Bio Inc. | Method for production of T cell population |
| JP5456689B2 (ja) | 2007-12-07 | 2014-04-02 | ミルテンイ バイオテック ゲーエムベーハー | 試料を少なくとも２つの成分に分離する遠心分離機 |
| WO2012143524A2 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2013188693A1 (en) * | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
-
2015
- 2015-05-08 EP EP15166966.0A patent/EP3091032A1/en not_active Withdrawn
-
2016
- 2016-05-06 US US15/572,134 patent/US20180112000A1/en not_active Abandoned
- 2016-05-06 ES ES16720842T patent/ES2954183T3/es active Active
- 2016-05-06 EP EP16720842.0A patent/EP3294766B1/en active Active
- 2016-05-06 WO PCT/EP2016/060148 patent/WO2016180721A1/en not_active Ceased
- 2016-05-06 CN CN201680026258.6A patent/CN107889492B/zh active Active
- 2016-05-06 CA CA2985251A patent/CA2985251C/en active Active
- 2016-05-06 JP JP2017558425A patent/JP6987640B2/ja active Active